TrialLeukemia & lymphoma2023

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Ryan D Cassaday et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.